Health Sciences Center, Room 292
1000 E. University Ave., Dept. 3375
Laramie, WY 82071
Phone: (307) 766-6120
Fax: (307) 766-2953
Email: uwpharmacy@uwyo.edu


mkandadi@uwyo.edu • (307) 766-6133 • Health Sciences Ctr 595
Biopharmaceutics and Pharmacokinetics
Kandadi MR, Unnikrishnan MK, Warrier AK, Du M, Ren J, et al. (2011) Chromium (D-phenylalanine)3 alleviates high fat-induced insulin resistance and lipid abnormalities. J Inorg Biochem 105: 58-62.
Turdi S, Kandadi MR, Zhao J, Huff AF, Du M, et al. (2010) Deficiency in AMP-activated protein kinase exaggerates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol.
Kandadi MR, Stratton MS, Ren J (2010) The role of Src homology 2 containing protein tyrosine phosphatase 2 in vascular smooth muscle cell migration and proliferation. Acta Pharmacol Sin 31: 1277-1283.
Kandadi MR, Rajanna PK, Unnikrishnan MK, Boddu SP, Hua Y, et al. (2010) 2-(3,4-Dihydro-2H-pyrrolium-1-yl)-3oxoindan-1-olate (DHPO), a novel, synthetic small molecule that alleviates insulin resistance and lipid abnormalities. Biochem Pharmacol 79: 623-631.
Kandadi MR, Hua Y, Ma H, Li Q, Kuo SR, et al. (2010) Anthrax lethal toxin suppresses murine cardiomyocyte contractile function and intracellular Ca2+ handling via a NADPH oxidase-dependent mechanism. PLoS One 5: e13335.
Hua Y, Kandadi MR, Zhu M, Ren J, Sreejayan N (2010) Tauroursodeoxycholic acid attenuates lipid accumulation in endoplasmic reticulum-stressed macrophages. J Cardiovasc Pharmacol 55: 49-55.
Gullapalli S, Amrutkar D, Gupta S, Kandadi MR, Kumar H, et al. (2010) Characterization of active and inactive states of CB1 receptor and the differential binding state modulation by cannabinoid agonists, antagonists and inverse agonists. Neuropharmacology 58: 1215-1219.
Sreejayan N, Dong F, Kandadi MR, Yang X, Ren J (2008) Chromium alleviates glucose intolerance, insulin resistance, and hepatic ER stress in obese mice. Obesity (Silver Spring) 16: 1331-1337.
Dong F, Kandadi MR, Ren J, Sreejayan N (2008) Chromium (D-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. J Nutr 138: 1846-1851.
